Skip to content

We truly advance precision oncology and identify clinical biomarkers where other methods fail

The discovery and development of biomarkers for precision medicine using single-cell data and AI fully exploits the power of cutting-edge technologies in translational research. We are paving the way for the development of new life-saving diagnostics and next-generation therapeutics for complex diseases.

We discover clinically-relevant biomarkers with single-cell analytics and AI

We discover clinically-relevant biomarkers with single-cell analytics and AI

We aim to improve clinical outcomes and shorten the drug development process by leveraging single-cell technologies and our proprietary AI platform ScaiVision.

Using our cluster-free, unbiased, and highly sensitive AI platform, we have built unique capabilities to discover new clinically-relevant biomarker signatures with diagnostic or stratification potential for clinics in several complex indications.

Scailyte provides a rapid and efficient end-to-end pipeline for extracting relevant biosignatures from single-cell data related to efficacy, toxicity or to the mode of action of therapeutics. These discoveries offer the basis for companion diagnostics and in-vitro diagnostic assay prototypes on common platforms in the clinic.

Read more

Use Case:

Patient stratification: ScaiVision predicts ICI response at baseline in metastatic NSCLC (Non Small Cell Lung Cancer)

Immunology and Oncology - Patient stratification: ScaiVision predicts ICI response at baseline in metastatic NSCLC v2

Working in close collaboration with our clinical partners we have discovered biomarker signatures in several disease areas

Indication
Clinical question
Technology
Tissue
#patients
Outcome and Status
Sezary Syndrome (CTCL)
Diagnosis of CTCL
CyTOF
PBMCs
60 + 33
0.98 AUC; patent filed (EP19219889)
Flow-cytometry antibody panel prototype
Endometriosis
Diagnosis of endometriosis
scRNA-seq
PBMCs
42 + 60
0.9 AUC; patent filed (EP21204845)
Clinical validation and assay development
scRNA-seq
Endometrium
35 + 30
0.9 AUC; patent filed (EP21204856)
Clinical validation and assay development
Covid19 / ARDS
Prediction of ARDS development in Covid19-patients
CyTOF
PBMCs
Clinical data
37 + 17
0.95 – 1 AUC
Roussel et al., Cell Reports Medicine 2021
Head and neck squamous cell carcinomas (HNSCC) (Radiotoxicity)
Prediction of toxicity
CyTOF
PBMCs Clinical data
41
0.89 AUC for binned toxicity scores
DLBCL (CAR-T Cells)
Prediction of therapy response and toxicity
scRNA-seq
Infusion cell product
23
0.8 AUC efficacy prediction
1 AUC toxicity prediction
Helping you speed up your therapy development and increase your success rate
Get in touch